Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection.
OBJECTIVE
To clarify the effect of early fosfomycin treatment, an antimicrobial agent in common use in Japan, on children with E. coli O157 with the aim of preventing hemolytic uremic syndrome (HUS).


METHODS



METHODS
Non-randomized prospective study for development of HUS among inpatients with E. coli O157.


METHODS
The hospitals where the 292 inpatients were treated.


METHODS
A total of 292 inpatients aged six to eleven years with E. coli O157 infection, 36 (12.3%) of whom were HUS cases.


RESULTS
Most of the HUS inpatients (91.7%) developed this complication between the sixth and ninth day of illness. We therefore analyzed the effects of antimicrobial therapy, especially that of fosfomycin, on prevention of HUS within the first five days of illness, because fosfomycin was the most frequently used (88.0%). To clarify the effect of fosfomycin alone on prevention of HUS, we carried out an analysis using the data for 130 inpatients who received fosfomycin alone or did not receive any antimicrobial agents, within the first five days of illness. multivariate analysis, controlled for age, gender and presence of fever, showed that all adjusted odds ratios for the development of HUS with the use of fosfomycin within the first three days of illness were less than 1.0, with the use of fosfomycin on the second day of illness achieving statistical significance (adjusted OR, 0.09; 95% CI, 0.01-0.79). Furthermore, inpatients who took fosfomycin within the first two days of illness developed HUS significantly less often than those who did not (adjusted OR, 0.15; 95% CI, 0.03-0.78). On the other hand, fosfomycin therapy on and after the third day of illness was not associated with the prevention of HUS.


CONCLUSIONS
The early use of fosfomycin within the first two days of illness might prevent the development of HUS.
Ikeda
K
K
Osaka University, Graduate School of Medicine, Department of Social and Environmental Medicine, Suita City, Japan.
Ida
O
O
Kimoto
K
K
Takatorige
T
T
Nakanishi
N
N
Tatara
K
K
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000150:complications / Q000517:prevention & control*; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D005578:Fosfomycin